NCT07468552|Not Yet RecruitingPhase 2DMC
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)
Loading search results
Sponsor study identifier
interventional
100
0 countries
N/A
Study Start
November 15, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
March 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 5, 2026
Actual (reported)March 12, 2026
Actual (reported)November 15, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Maximum Tolerated Dose (MTD)
The maximum tolerated dose defined as the median dose within the FDA-recommended range, at which dose increase is not recommended (based on standardized and health care provider assessments).
24 weeks (Treatment Phase)
Days of Abstinence
Number of days per week with no cannabis use, as assessed by Timeline Follow Back (TLFB).
24 weeks (Treatment Phase)
Severity of Cannabis Use Disorder (CUD)
24 weeks (Treatment Phase)
Negative Urine Drug Screens (UDS)
24 weeks (Treatment Phase)
Cannabis Craving
24 weeks (Treatment Phase)
1. Cannabis Withdrawal
24 weeks (Treatment Phase)
Retention in Treatment
Week 24 (End of Treatment Phase)
Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will be made based on the Dose Increase Checklist and shared decision between the site study physician (MD or DO) and the participant.
Participants will receive weekly masked injections of placebo.
Jia Bei Wang, MD, PhD
NIDA/NIH, Division of Therapeutics and Medical Consequences (DTMC)
First Submitted
March 5, 2026
First Posted
March 12, 2026
Study Start
November 15, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Tirzepatide to Slow Biological Aging
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 15, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 21, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: